cyrilzakka/clinical-trials huggingface dataset:
Personalized Recommendation System for Sport Activities

The goal of this clinical trial is to test and compare the effects of a tailored algorithm recommendation of sport activities concreted in challenges to improve some critical performance dimensions.

Q1: Improving participant performance is achieved by using personalized sports activity recommendation using an algorithm and tracking compliance using a decentralized application (dApp)? Q2: Are participants satisfied with the performance and simplicity of the dApp used?

Participants will be asked to do specific activities recommended by the developed recommender system. The activities to be carried out will be conditioned by the profile obtained from each participant at the beginning of the intervention. They will consist of reinforcement activities for the dimensions with the lowest scores.

Researchers will compare a experimental group and a control group to see if the dimensions assessed at the beginning of the intervention were improved.


Eligibility Criteria:
Inclusion Criteria:

* Amateur football players.
* Aged between 14 and 18 years old.
* Without any injury.
* The ones who can attend the assessing sessions and fill in the informed consent form.

Exclusion Criteria:

* Aged different from the indicated above.
* Injured.
* Missing one of the assessing sessions.
* Not performing the proposed training twice, or not registering two or more training sessions.
Early Lymph Node Metastasis in T1/2 Stage Colorectal Cancer: Molecular and Clinical Insights

The prognostic implications of lymph node metastasis in colorectal cancer patients at an early stage, specifically T1/2 stage, are relatively unfavorable. Therefore, understanding the clinical and molecular traits relevant to metastasis in T1/2 stage are of substantial clinical importance.

Patients were classified based on their lymph node staging, with an ancillary categorization into MSI-H and MSS subgroups. A comparative mutational study was performed among these groups, incorporating risk stratification and Receiver Operating Characteristic curve analysis, with the aim of discerning the predictability of clinical features integrated with molecular characteristics for early metastasis in T1/2 stage colorectal cancer.

Eligibility Criteria:
Inclusion Criteria:

* Men and women aged 18-75 years old;
* Clinical staged T2;
* Histologically proven colon or rectal adenocarcinoma.

Exclusion Criteria:

* Patients over 80 years of age;
* Recurrent colorectal cancer;
* Multiple primary tumors;
* Distant metastasis.
Trial Comparing Iron Supplementation Versus Routine Iron Intake in Very Low Birth Weight Infants

In preterm infants with birth weights less than 1500 grams, does iron supplementation with 2mg/kg/day in addition to routine feeding with routine iron-fortified milk (formula or fortified mother's milk), as compared to routine iron fortified milk, increase hematocrit at 36 weeks adjusted postmenstrual age (or at discharge if sooner)?

Fortified mother's milk or fortified formula is routine practice in neonatal units and is not an intervention.

Eligibility Criteria:
Inclusion Criteria:

* Birth weight \<1500 grams
* Tolerating iron fortified preterm formula or fortified human milk at 120cc/kg/day by 8 weeks of age
* \</= 32 weeks adjusted post-menstrual age at the time of enrollment

Exclusion Criteria:

* Cyanotic heart disease
* Bowel resection prior to enrollment
Investigation of Spinal Posture and Anthropometric Characteristics of Women with Chronic Constipation

The aim of this study was to compare the spinal posture and anthropometric characteristics of women with Chronic Constipation (CC) and healthy women.


Eligibility Criteria:
Inclusion Criteria:

* Inclusion criteria for women with chronic constipation:

  * Constipation according to Rome IV criteria between the ages of 18-65
  * Volunteer
  * Literacy
* Inclusion criteria for healthy women:

  * No constipation according to Rome IV criteria between the ages of 18-65
  * Volunteer
  * Literacy

Exclusion Criteria:

* Cancer, neurological disease, serious or uncontrolled systemic or metabolic disease

  * Being pregnant
  * Having a mental problem that will prevent cooperation
  * Having alarm symptoms over the age of 50
  * Having a diagnosis of secondary constipation
  * Being BMI\&gt;35
  * Having megacolon/megarectum and inactive (lazy) bowel syndrome
  * Having had colostomy surgery
  * Having a history of recent abdominal surgery
  * Having an open wound or local tumor in the abdominal region
  * Having an abdominal hernia
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Adults Aged >= 18 and <= 64, Plus Revaccination

Immunogenicity and safety of a cell-derived influenza vaccine in adults aged \>= 18 and \<= 64 years, plus revaccination


Eligibility Criteria:
Inclusion Criteria

1. Willing and able to give informed consent and able to adhere to all protocol required study procedures.
2. Men and women aged \>= 18 and \<= 64 years.
3. Being in good health as judged by medical history, physical examination and clinical judgment of the investigator.

Exclusion Criteria

1. Known to be allergic to constituents of the vaccine.
2. A serious adverse reaction after a previous (influenza) vaccination. Presence of any significant condition that may prohibit inclusion as determined by the investigator.
3. Having received vaccination against influenza or lab confirmed influenza within the previous six months before study vaccination.
Effects of Itopride on Gastric Motor and Sensory Functions in Healthy Volunteers

Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms associated with gastroparesis. Due to inadequate gastric emptying, these patients often have symptoms of bloating, nausea and vomiting following ingestion of a meal. This is a randomized, parallel group, two dose double blind, placebo-controlled study evaluating the effects of itopride (100 mg and 200 mg three times daily) and placebo on gastric motor and sensory functions in healthy volunteers.

In order to compare the effects of two itopride doses (100 mg and 200 mg three times daily) and placebo on gastric emptying and small bowel transit, gastric accommodation, and postprandial symptoms in female and male healthy volunteers, the following methods, which have been extensively used and validated in the laboratory, will be used:

Scintigraphic gastric emptying of solids and small bowel transit; single photon emission computed tomography to measure gastric accommodation; and the nutrient drink test to measure maximum tolerated volume and postprandial symptoms.

Based on data acquired using the same methods in the laboratory, the sample size of 15 subjects per group provides 80% power to detect an effect size of 16% in the primary endpoint of the study, that is a change in gastric volume (postprandial - fasting). This magnitude of change is considered clinically relevant.

Eligibility Criteria:
Inclusion Criteria:

1.Non-pregnant, non-breastfeeding females 2.18 years of age or older 3.Body mass index between 20 and 32 kg/m2 4.No alarm indicators on clinical assessment (weight loss of more than 7 kg, bleeding, recent recurrent vomiting, progressive dysphagia).

5.No history suggestive of small bowel obstruction

Exclusion Criteria:

1. Patients who have any gastrointestinal symptoms. Do not fulfill the criteria for the irritable bowel syndrome or functional dyspepsia clinically
2. Patients with a clinical diagnosis of gastroparesis or an alternative underlying disease that could be responsible for disturbed gastric function e.g. diabetes, post-vagotomy, post-fundoplication
3. Abdominal surgery other than appendectomy, cholecystectomy, hysterectomy, caesarian section or tubal ligation
4. Positive symptoms on an abridged bowel disease questionnaire
5. Use of medications that may alter gastrointestinal motility including metoclopramide, domperidone, tegaserod; acetaminophen and ibuprofen will be allowed
6. Current use of medications which may interact with the study medications
7. Patients who have taken any investigational medications within the past 30 days
8. Over the counter medication (except multivitamins) within 7 days of the study
9. Chronic gastrointestinal illness or any systemic disease that could affect gastrointestinal motility for controls
10. Known intolerance or allergy to eggs, milk and Ensure
11. History of chronic diarrhea
Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects

This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of PF-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.


Eligibility Criteria:
Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

* Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests).
* Women must be of non childbearing potential.
* Body Mass Index (BMI) of 25 to 35 kg/m2 inclusive; and a total body weight \>50 kg (110 lbs).
* An informed consent document signed and dated by the subject.
* Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
* Evidence or history of any chronic ongoing or current pulmonary disease.
* History of smoking in the past 5 years and a history of smoking more than 10 pack years, or history or evidence of habitual use of other (non smoked) tobacco or nicotine containing products. Active ocular disease including infection, glaucoma, seasonal allergies, dry eye symptoms or retinal/optic nerve disease.
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease.

A Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Participants with Stable Coronary Heart Disease.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of stable coronary heart disease prior to screening
* Currently receiving high intensity statin(s)

Exclusion Criteria:

* Unstable cardiovascular conditions
* Any planned arterial revascularizations
* Fasting Laboratory values at screening: Triglycerides \> 500 mg/dl, Low Density Lipoprotein-Cholesterol \> 100 mg/dL
* Any disease or condition or laboratory value that would place the participant at an unacceptable risk.
MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis

The aim of this study is the quantitative determination of bone-specific microRNAs in the serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic therapy.

Primarily the influence of the therapeutic treatment on the microRNA concentration in the serum (treatment-response) and the relation between microRNA serum levels and changes of the bone mineral density will be investigated.

These data will help to examine the use of microRNAs as novel diagnostic biomarkers for the diagnosis of osteoporosis and targeted therapeutic treatment of patients.

Eligibility Criteria:
Inclusion Criteria:

* Postmenopausal women
* Age 60-80 years
* T-score according to DXA: \<-2.5
* indication for osteoporosis therapy according to international guidelines

Exclusion Criteria:

* Diabetes mellitus type 1
* renal insufficiency III-V °
* Cirrhosis hepatis (Child B or higher)
* Chronic alcohol abuse
* rheumatic disease (RA, SpA, SLE)
* Malignancies (\<5 years)
* Eating Disorder (anorexia nervosa, bulimia)
* bone-specific pretreatment (DMAB, TPTD, strontium ranelate, SERMs) Bisphosphonate treatment is allowed
A Study of JNJ-64251330 in Healthy Participants

The purpose of this study is to evaluate: systemic and local gut (rectum and sigmoid colon) exposure to JNJ-64251330, local tissue Pharmacodynamics (PD) using gut (rectum and sigmoid colon) biopsies (Part 1) and the effect of food on the rate and extent of absorption of JNJ-64251330 from oral tablet dosed with or without food (Part 2).


Eligibility Criteria:
Inclusion Criteria:

* Body mass index (BMI; weight \[kilogram {kg}\]/height\^2 \[meter {m}\]\^2) between 18.0 and 30.0 kilograms per meter square (kg/m\^2) (inclusive), and body weight not less than 50.0 kg
* 12-lead electrocardiogram (ECG) consistent with normal cardiac conduction and function, including: QTc interval less than or equal to (\<=) 450 milliseconds (ms) for men and \<= 470 ms for women
* Healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, lipid panel, hematology, coagulation or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator
* Have participant-reported normal consistency, regular bowel movements
* A woman must have a negative highly sensitive serum (beta-human chorionic gonadotropin \[hCG\])

Exclusion Criteria:

* History of hepatic or renal insufficiency; significant cardiac, vascular, pulmonary, endocrine, hematologic, rheumatologic, neurologic, oncologic, or psychiatric disease, or metabolic disturbances or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results
* Active or chronic infection, a nontuberculous mycobacterial infection, or opportunistic infection (example, pneumocystosis and aspergillosis)
* History of severe allergic reaction to midazolam
* Contraindications to the use of tofacitinib per summary of product characteristics (SmPC)\^14/ local prescribing information
* Female participant who is a breastfeeding mother
The Pilot Study of Medical Device-Neuclare for Patients With Mild Cognitive Disorder and Early Dementia

This clinical trial aims to explore the effectiveness and safety of cognitive function improvement of Neuclare, a science medical device, for patients with mild cognitive impairment and early Alzheimer's disease.

Through methods such as Trail Making Test Black \& White, Attention Questionnaire Scale(AQS), Neuropsychiatric Inventory (NPI), etc, cognitive function improvement before and after using Neuclare will be evaluated.


Eligibility Criteria:
Inclusion Criteria:

* Adults aged 55 to 90
* Patients who meet "Probable Alzheimer's disease" and "Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)" criteria for dementia
* Patients with CDR (clinical dementia rating) from 0.5 to 1 and MMSE-II over 18
* Upon hearing and fully understanding the detailed explanation of this clinical trial, a person who has voluntarily decided to participate and agreed in writing to comply with the precautions

Exclusion Criteria:

* Patient with pathological lesions in the brain identified by MRI
* Patients with metabolic disorders such as thyroid dysfunction, hyperglycemia, hypoglycemia, liver or kidney dysfunction, and long-term use of drugs that will cause cognitive decline (e.g., anticholinergic drugs)
* History of epileptic seizures or depression or psychiatric abnormalities or with visual acuity and fluctuations in cognitive decline
* History of psychiatric disorder other than the inclusion criteria.
* A person with a severe history of cancer/tuberculosis
* A person who has or is taking psychiatric or peripheral/central nervous system drugs
* A person who has contact dermatitis or sensitive skin abnormalities
* Patients with a high fever of 40 degrees or higher based on eardrum body temperature
* A person whose bleeding is identified within the last 3 months due to a common procedure/surgery that may affect vital signs
* A person who is unable to perform MRI tests
* Pregnant women
* Patient with calcification in the brain identified by CT
* Patient with allergic to contrast agents such as Definity or Gadovist
* Other cases where the investigator judged that it is difficult to participate in the study;
Evaluation Direct and Indirect Composite Restoration in Hypomineralization Molars.

The aim of this study is to evaluate the effectiveness of direct and Indirect Composite Restoration in Children With Molar Incisor Hypomineralization Patients (MIH) and following up after 3 , 6 , 12 months (Clinically):

Group A ( Control group ): Hypomineralization molars were restored by direct composite.

Group B ( Experimental group ): Hypomineralization molars were restored by indirect composite.

Pediatric dentists face a high prevalence of MIH ranging from 3 to 40%, so it is relatively common condition that would cause treatment challenges due to severe sensitivity, breakdown of the occlusal surface, difficulty anesthesia and relatively high failure of restorations as a result of marginal breakdown of restorations.

There are many treatment options available to restore these teeth. In mild and moderate cases, they are restored using direct composite resin. In cases where teeth are severely affected, the treatment is more complicated, including stainless steel crowns and different types of full or partial indirect crowns.

Direct composite resin restorations are the treatment option in the majority of clinical cases, but in severe cases, the results of treatment are often unsatisfactory.

Indirect composite restorations are an aesthetic alternative to cast metal inlays and stainless steel crowns with minimal microleakage.

Eligibility Criteria:
Inclusion Criteria:

1. Age between 8 and 12 years.
2. Definitely positive or positive ratings of Frank scale.
3. The first permanent molars must achieve the following criteria: The molar must be suffering from severe demineralization and it must be restorable with composite.
4. caries lesions include the occlusal surface and should not extend more than thirds of the thickness of dentin
5. Absence clinical and radiographic signs which indicate pulp necrosis

Exclusion Criteria:

1. Systematic or mental disorders.
2. Definitely negative or negative ratings of Frankel scale
3. Existence periapical translucence
4. Existence external or internal abnormal absorption
5. Existence swelling or fistula
6. Sensitivity to percussion
7. Existence of spontaneous or stimulant pain
Immersive Care - Virtual Mirror Therapy

The purpose of this implementation study is - primarily - to investigate the feasibility, acceptability, tolerability of a new virtual reality application in stroke patients, and -secondarily - to gain initial insights in the preliminary clinical effects of this application.

Although immersive technologies have great potential in healthcare, they are still relatively unknown and underutilized in this field. In this study a new virtual reality (VR) application will be implemented and tested in two groups of stroke patients (10 acute phase/10 chronic phase). In an attempt to reactivate the affected upper limb in stroke patients, therapists often use mirror therapy. Using a mirror, the movement of a paralyzed limb is feigned in order to reprogram the brain. A patient performs exercises with the healthy limb, but through the mirror the patient seems to use the affected limb. A high number of repetitions is essential to stimulate the so-called neuroplasticity of the brain, but this makes mirror therapy monotonous. In addition, the therapy also has its limitations. Activities are limited by the physical boundaries of the modality, with exercises largely limited to distal movements and simple functional activities. Larger, free-standing mirrors provide a wider range of motion for therapeutic activities, but offer less protection against environmental distraction. With VR, these obstacles can be overcome. By focusing on virtual mirror therapy using a VR headset, therapists hope to create a more pleasant and realistic experience for the patients.

Eligibility Criteria:
Inclusion Criteria:

* Stroke patients in the subacute or chronic phase, aged between 18 and 85 years old with a normal functioning upper limb on the unaffected side and a reduced use and / or weakness and / or paralysis of the upper limb on the affected side
* Ability to sit on a chair or in a wheelchair with adequate trunk stability so that the unaffected upper limb can move freely
* Ability to follow verbal instructions
* Ability to communicate verbally with the researchers

Exclusion Criteria:

* Stroke patients in acute phase
* Severe medical conditions that interfere with the proper execution of the research
* Patients who are medically unstable
* Cognitive disorders which may complicate the research or make it impossible
* Speaking disorders (aphasia, dysarthria) which may complicate the proper execution of the research and the communication of important verbal information
* Visual disorders which complicate carrying out ADL activities or make it impossible
* Known allergies to any of the materials of the VR headset
* Epilepsy
* Extreme sensitivity to motion sickness
* Specific anxiety disorders that hinder the use of the VR headset such as claustrophobia
* Skin diseases or lesions in the contact area of the VR headset